Fig. 2.
Metabolic imaging of tumor response. Low-dose CT (top) and 18F-FDG PET/CT (bottom) fusion of the transaxial left mid-abdominal mesenteric mass. a One month prior to starting treatment with crizotinib (max. SUV = 5.5; mass measures 3.6 cm by 2.8 cm AP). b Three months after starting treatment with crizotinib (max. SUV = 2.0; indicates that the minimal residual mass is metabolically inactive).